Simple Summary The FDA recently approved a fourth approach (in addition to surgery,
radiation therapy, and chemotherapy) for treating glioblastoma; namely, tumor treating fields …

Glioblastoma is the most common yet most lethal of primary brain cancers with a one-year
post-diagnosis survival rate of 65% and a five-year survival rate of barely 5%. Recently the …

Exposing cancer cells to alternating electric fields of 100-300 kHz frequency and 1-4 V/cm
strength has been shown to significantly reduce cancer growth in cell culture and in human …

Aims Tumor electric fields therapy (TTFields) is emerging as a novel anti‐cancer
physiotherapy. Despite recent breakthroughs of TTFields in glioma treatment, the average …

Despite improved survival outcomes across many cancer types, the prognosis remains grim
for certain solid organ cancers including glioblastoma and pancreatic cancer. Invariably in …

Abstract Tumor Treating Fields (TTFields), a new modality of cancer treatment, are electric
fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment …

Introduction As a novel treatment modality, tumor treating fields (TTFields) exert low-
intensity, medium-frequency electric fields on tumor cells. TTFields' effectiveness and safety …

Tumor treating fields (TTFields) represent a novel FDA-approved treatment modality for
patients with newly diagnosed or recurrent glioblastoma multiforme. This therapy applies …

Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate
frequency (200kHz), which have been demonstrated to block cell division and interfere with …

Simple Summary Glioblastoma (GBM) is the most common malignant primary brain tumor.
Although the standard of care, including maximal resection, concurrent radiotherapy with …